India's Leading Healthcare & Pharma Companies 2023

India’s Leading Healthcare & Pharma Companies 2023 | 1 [ MESSAGE FROM MD’S DESK ] INDIAN HEALTHCARE & PHARMA: PRESCRIPTION FOR FUTURE GROWTH Healthcare and pharmaceuticals industry have been contributing significantly to the Indian economy through capital investments, employment generation, fostering innovation and ESG initiatives. The industry comprises of pharmaceuticals, medical devices and healthcare services including hospitals, diagnostics, and health-tech companies. The industry growth is driven by factors such as shift in demographics mix, increase in incidences of lifestyle and chronic diseases, improved awareness about health and wellness together with public and private sector spends. Dun & Bradstreet India is pleased to launch the inaugural edition of its premier publication, “India’s Leading Healthcare & Pharma Companies 2023” . We at Dun & Bradstreet identify a central theme which is extremely critical and current to the healthcare & pharma fraternity. This year, the central theme is “Prescription for Future Growth” . The recent pandemic caused severe disruption and highlighted the value of health from both an economic and human potential perspective. It has highlighted the need to devote additional resources for investing in high-quality healthcare, prevention of future epidemics and to manage such crises without excessive economic disruption. The Indian healthcare industry, today, offers a dynamic set of opportunities as well as challenges. The yawning gap between the demand and supply of healthcare infrastructure has been the driving force of investments into the industry. The government is also taking proactive measures to up the quality of healthcare deliverables at affordable costs. Dun & Bradstreet India has a rich heritage of working closely with healthcare and pharma companies, irrespective of their age, size and standing. D&B enables you to make data-driven decisions by empowering you with a variety of data and analytics- driven products and solutions. D&B has received 90 thousand checks from global entities on Indian pharmaceutical companies during 2022. These checks are generally from buyers, business partners, JV partners and other stakeholders, and help them ascertain the credibility and improve global positioning. To summarize, D&B provides an independent and comprehensive assessment of the healthcare and pharma companies encompassing various aspects, viz. financial, operational, business, management, risks, and challenges. I have no doubt that the Healthcare & Pharma industry will see more action in the days to come, and Dun & Bradstreet India will continue to be your most reliable knowledge partner in this endeavour. Avinash Gupta Managing Director & CEO – India Dun & Bradstreet Dun & Bradstreet